ReviewMolecular psychiatry2026
Advances in chemogenetics: a review of DREADDs and its application in psychiatric disorders.
Review in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Histamine HMolecular psychiatry · 2026Article
- Overview of the DREADDs chemogenetics and the patent landscape of their actuators.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Next-generation chemogenetic inhibition using a brain-permeant non-prescription agent.Signal transduction and targeted therapy · 2026Article
- Context-dependent effects of SOM neurons to enhance the responses of corticocollicular neurons to repetitive sounds.iScience · 2026Article
- Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Genetic manipulation technologies for precise cellular control: a comparative review of five approaches.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemogenetics is a rapidly advancing field that uses genetically engineered receptors to selectively modulate the activity of specific neuronal populations in the brain. This innovative approach allows for precise control of neural circuits, providing valuable insights into the roles of specific circuits in behavior and disease mechanisms. The potential of chemogenetics to transform our understanding of brain function could lead to novel therapeutic strategies for a wide range of neurological and psychiatric disorders. This review explores the fundamental mechanisms of chemogenetics, with a focus on Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) and their associated ligands. We provide a comprehensive overview of the various classes of DREADDs, detailing optimal ligand dosing and offering guidance for their integration into both research and clinical settings. Additionally, we examine the recent applications of DREADDs in psychiatry, particularly about brain regions and circuits involved in anxiety.
Indexed as
Identifiers
41107438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.